Evidence map›Paper›PMID 41392102›Full record

ArticleScientific reports2025

A novel, non-spirometric "BMP index" for predicting severe adverse outcomes in fibrosing interstitial lung diseases.

Tang-Hsiu Huang, Hsin-Yu Hou, Han-Yu Chang, Chia-Hao Hu, Hung-I Kuo, Hong-Ping Er, Yu-Wei Wu, Chien-Yu Lin, Yau-Lin Tseng, Ju-Ming Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tang-Hsiu HuangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hsin-Yu HouDivision of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Han-Yu ChangDivision of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chia-Hao HuDivision of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hung-I KuoChest Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
Hong-Ping ErChest Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
Yu-Wei WuDivision of Chest Medicine, Medical Department, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
Chien-Yu LinInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yau-Lin TsengDivision of Thoracic Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ju-Ming WangDepartment of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan.
Li-Ting HuangDepartment of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chia-Tse WengDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Sheng-Hsiang LinInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chi-Chang ShiehInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. cshieh@mail.ncku.edu.tw.
Chao-Liang WuDepartment of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. wumolbio@mail.ncku.edu.tw.

Funding

National Cheng Kung University Hospital NCKUH-11306007National Science and Technology Council of Taiwan NSTC 113-2327-B-006-001
6 · The paper itself

Abstract

Fibrosing interstitial lung diseases (fILDs) exhibit diverse clinical courses and prognoses, with no established biomarkers for predicting acute exacerbation (AE) and early death. This study introduces a novel composite "BMP index", integrating body mass index (BMI), mucin-1, and pentraxin 3 (PTX3) to assess AE and early death risk in fILDs. Between January, 2017, and May, 2025, we enrolled 366 patients with fILDs diagnosed, managed and followed at three hospitals in southern Taiwan. Using stratified randomization with a ratio 3:2, participants were assigned to derivation (218 patients) and validation (148 patients) cohorts. Baseline circulating mucin-1 and PTX3 levels were measured via enzyme-linked immunosorbent assay. One point was assigned for each of the three components of the BMP index: BMI < 24 kg/m

Indexed as

Lung Diseases, InterstitialMucin-1Serum Amyloid P-ComponentAgedBiomarkersBody Mass IndexC-Reactive ProteinFemaleHumansMaleMiddle AgedPrognosisSeverity of Illness IndexTaiwanBiomarkersC-Reactive ProteinMUC1 protein, humanMucin-1Serum Amyloid P-ComponentAcute exacerbationBody mass indexMortalityMucin-1Pentraxin 3Pulmonary fibrosis

Identifiers

PMID41392102
PMCPMC12824404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.